Dravet Syndrome

Stoke Therapeutics Inc (NASDAQ: STOK) announced highlights from five presentations related to the ongoing clinical development of STK-001 being made at the American Epilepsy Society 2021 Annual Meeting. STK-001 is under development to target the underlying cause of Dravet syndrome,...

Stoke Therapeutics Inc (NASDAQ: STOK) announced interim analysis data from Phase 1/2a MONARCH study of STK-001 in children and adolescents with Dravet syndrome. The interim analysis is based on data from 21 patients who were treated in the single 10mg (n=5), 20mg (n=4), or 30mg (n=6...

Biotech stocks present an exciting investment opportunity, given the heady gains they can fetch if one places the right bet at the right time. The IPO Terms Stoke Therapeutics, Inc. this week proposes to offer 6.7 million shares at an estimated price range of $14-$16, according to an amended S-1...

Zogenix, Inc. (NASDAQ: ZGNX), which develops therapies for rare diseases, said Monday afternoon the FDA issued a refusal to file letter regarding its NDA for Fintepla, chemically fenfluramine hydrochloride, which is being evaluated for the treatment of seizures associated with Dravet syndrome. The...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) announced incremental positive news on its lead cannabinoid product candidate Epidiolex, sending the stock higher. What Happened GW Pharma announcedpositive results for a second, late-stage study that evaluated its Epidiolex oral solution for treatment...

Zogenix, Inc. (NASDAQ: ZGNX) peaked nearly 30 percent in Thursday's pre-market session after management released positive top-line results from its second pivotal Phase 3 study of ZX008 in Dravet Syndrome. The trial met primary and secondary endpoints and demonstrated statistical significance...

Shares of Zogenix, Inc. (NASDAQ: ZGNX) traded higher by 200 percent early Friday morning after the company announced top-line results from a phase 3 clinical trial exploring its drug called ZX008 for the treatment of Dravet syndrome. Zogenix said that its trial met its primary objective of...